Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 18;13(2):325-341.
doi: 10.18240/ijo.2020.02.18. eCollection 2020.

Biomarkers in retinoblastoma

Jie Sun  1 , Hui-Yu Xi  1   2 , Qing Shao  1 , Qing-Huai Liu  1
Affiliations
Review

Biomarkers in retinoblastoma

Jie Sun et al. Int J Ophthalmol. .

Abstract

Retinoblastoma (RB) is the most common intraocular malignancy of childhood caused by inactivation of the Rb genes. The prognosis of RB is better with an earlier diagnosis. Many diagnostic approaches and appropriate clinical treatments have been developed to improve clinical outcomes. However, limitations exist when utilizing current methods. Recently, many studies have identified identify new RB biomarkers which can be used in diagnosis, as prognostic indicators and may contribute to understanding the pathogenesis of RB and help determine specific treatment strategies. This review focuses on recent advances in the discovery of RB biomarkers and discusses their clinical utility and challenges from areas such as epigenetics, proteomics and radiogenomics.

Keywords: biomarkers; epigenetics; proteomics; radiogenomics; retinoblastoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Pathogenesis of RB.
Figure 2
Figure 2. Detection of RB.
Figure 3
Figure 3. Clinical applications of biomarkers in RB.
See this image and copyright information in PMC

References

    1. Dimaras H, Corson TW, Cobrinik D, White A, Zhao JY, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F, Gallie BL. Retinoblastoma. Nat Rev Dis Primers. 2015;1:15021. - PMC - PubMed
    1. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93(9):1129–1131. - PubMed
    1. Hahn SM, Kim HS, Kim DJ, Lee SC, Lyu CJ, Han JW. Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma. Pediatr Hematol Oncol. 2016;33(1):74–82. - PubMed
    1. Shields CL, Say EA, Pointdujour-Lim R, Cao C, Jabbour PM, Shields JA. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr Ophtalmol. 2015;38(6):542–549. - PubMed
    1. Shields CL, Lally SE, Leahey AM, Jabbour PM, Caywood EH, Schwendeman R, Shields JA. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol. 2014;25(5):374–385. - PubMed

LinkOut - more resources